Table 4 Most common grade ≥ 3 AEs (in >5% of the overall population)

From: Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

  All patients (N = 65) Patients who did not proceed to SCT (N = 42) Patients who received maintenance (N = 25)a
n (%)    AE onset in cycles 1–12 (IRd) AE onset in cycle 13+ (single-agent ixazomib)
Neutropeniab 14 (22) 9 (21) 4 (16) 2 (8)
Thrombocytopeniab 9 (14) 7 (17) 2 (8) 1 (4)
Diarrhea 6 (9) 4 (10) 0 0
Fatigue 6 (9) 6 (14) 5 (20) 0
Back pain 5 (8) 2 (5) 1 (4) 0
Dehydration 5 (8) 5 (12) 0 1 (4)
Hypokalemia 5 (8) 4 (10) 2 (8) 1 (4)
Lymphopenia 6 (9) 4 (10) 3 (12) 1 (4)
Anemia 4 (6) 4 (10) 2 (8) 0
Hypertension 4 (6) 2 (5) 1 (4) 1 (4)
Hypophosphatemia 4 (6) 4 (10) 3 (12) 0
Leukopenia 5 (8) 5 (12) 1 (4) 0
Rashes, eruptions, and exanthemsc 4 (6) 4 (10) 3 (12) 0
PN NECc 4 (6) 2 (5) 0 0
Pneumonia 4 (6) 3 (7) 1 (4) 2 (8)
Vomiting 4 (6) 1 (2) 0 0
  1. AE adverse event, NEC not elsewhere classified, PN peripheral neuropathy, SCT stem cell transplantation
  2. aData are split to represent AEs during IRd induction (cycles 1–12), and single-agent ixazomib maintenance; patients could have had a new-onset AE in both treatment periods
  3. bPooled terms
  4. cData represent higher-level terms